Announcements & News
The Company has proceeded with the payment of the Bond Interest
Setting of Record Date for the upcoming Bond interest payment.
The Company has published the year’s end Share Dispersion Report
Updating the investing public regarding the 2024 Business Plan.
The Interim Financial Statements 2024 have been approved.
The results of the Annual General Meeting of the Company are available
Materials for Annual General Meeting of the Company 2024
Approval of financial statements 2023 and date set for AGM 2024
See the Company’s presentation to institutional investors at the Athex Group today
Vianex S.A. and its CEO share their thoughts on the partnership with our Company.
The Company has proceeded with the payment of the Bond Interest
The company has entered into a strategic partnership with Vianex S.A.
Setting of Record Date for the upcoming Bond interest payment.
The Company has published the year’s end Share Dispersion Report
Updating the investing public regarding the 2023 Business Plan.
Results of the Extraordinary General Meeting of the Company have been published
The Interim Financial Statements 2023 have been approved.
The Company has successfully listed its second tranche of Bonds on the CSE.
Calling of the Extraordinary General Meeting of the Company
The Company has proceeded with the issue and allotment of a second tranche of Bonds
See the Company’s press release regarding its participation at the 31st National Psychiatric Summit
The results of the Annual General Meeting of the Company are available
The Greek NHS has approved the coverage of PGx-CNS product
iDNA Genomics Public Ltd successfully lists Bond 2028 on the CSE
Materials for Annual General Meeting of the Company 2023
Approval of financial statements 2022 and date set for AGM 2023
Issue of Corporate Bonds
Issue of 160.333 additional Shares following results of EGM 29.12.22
Results of the Extraordinary General Meeting of the Company
Updating the investing public regarding the 2022 Business Plan.